Hinge Health, Inc. (HNGE) Stock Analysis and Metrics

Hinge Health

NYSE: HNGE

$74.30 ▼ -2.39 (-3.12%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap6.02 Bn

P/E-11.77

P/S9.31

Div. Yield0.00

Revenue Growth (1y) (Qtr)47.23

Add ratio to table…

About

Hinge Health, Inc. is a technology platform that delivers artificial intelligence powered musculoskeletal care to help individuals treat and prevent joint and muscle pain. The company combines AI driven motion tracking, a wearable nerve stimulation device, and a virtual care team of licensed physical therapists, physicians and health coaches to provide personalized exercise therapy and education. It operates in the digital health industry focusing on musculoskeletal disorders.

Hinge Health generates revenue primarily through subscription contracts with employers, health plans and government entities for access to its digital musculoskeletal platform. Revenue comes from the core care programs, the Enso wearable device for pain relief and the HingeSelect in person provider network which connects members to vetted clinicians at reduced rates. The company serves self insured employers, fully insured health plan populations, Medicare Advantage members and federal insurance plans.

Hinge Health holds a leading position in the digital musculoskeletal care market, competing with companies such as Sword Health, Kaia Health, Omada Health and Vori Health as well as with health plans that develop their own digital solutions. The company’s competitive advantages stem from its proprietary AI powered motion tracking technology, its extensive patent portfolio covering motion sensing and nerve stimulation, its ability to deliver clinically validated outcomes that reduce surgery rates and medical costs, and its scalable direct and partner driven sales model.

Hinge Health serves a diverse customer base that includes self insured employers ranging from large national corporations to public sector entities such as state and local governments and labor unions. The company also works with fully insured health plan populations, Medicare Advantage programs and federal insurance plans. Through its partnership model Hinge Health collaborates with organizations including Accolade Inc, Carrum Health Inc, Castlight Health Inc, Employer Direct Healthcare doing business as Lantern Specialty Care, Personify Health Inc, Progny Inc, Quantum Health Inc, Teladoc Health Inc and Vera Whole Health Inc. Additionally the company’s partners comprise the five largest national health plans by self insured lives and the top three pharmacy benefit managers by market share.

Investment Thesis

▲ Bull case

Hinge Health's Q1 FY26 results demonstrated strong momentum, with revenue growing 47% year-over-year to $182 million, surpassing guidance. This growth was driven by the strength of their platform, which automates care delivery, improves member outcomes, and lowers costs. The company's calculated billings for the last twelve months reached $770 million, reflecting a 52% growth from the previous year. This performance indicates a robust demand for their services and a scalable business model that is efficiently leveraging AI and automation to drive growth. The company's ability to consistently outperform expectations suggests that the market may be underestimating the long-term growth prospects of Hinge Health, particularly as they expand into new areas such as migraine care.
The launch of the migraine care program represents a significant growth catalyst for Hinge Health. The program has already been adopted by over 125 clients, representing more than 2 million eligible lives, within weeks of its launch. This rapid adoption underscores the strong demand for the company's innovative solutions and the potential for significant revenue growth in the future. The migraine care program leverages the company's existing platform capabilities, including the Enso neuromodulation device, which has received FDA 510(k) clearance for migraine care. This expansion into adjacent conditions demonstrates the company's ability to leverage its proprietary data and distribution network to drive future growth. The market may be underestimating the revenue impact of this program, which is expected to be meaningful beginning in 2027.
Hinge Health's financial performance continues to demonstrate the scalability and durability of its business model. The company achieved a gross margin of 85% and an operating margin of 25% in Q1 FY26, reflecting continued care team and hardware efficiency as the platform scales. Free cash flow was $42 million, a tenfold increase year-over-year, resulting in a 23% margin. These strong financial metrics indicate that the company is generating significant cash flows, which can be reinvested in innovation and growth or returned to shareholders. The company's ability to scale efficiently while maintaining strong profitability suggests that it is well-positioned to capitalize on future growth opportunities.
The company's strategic investments in AI and operational efficiencies have enabled it to improve gross and operating margins while scaling member engagement. This has supported a meaningful ramp in both free cash flow and share repurchases. The company's ability to leverage AI to drive operational efficiencies and improve member engagement suggests that it is well-positioned to maintain its competitive advantage in the digital musculoskeletal (MSK) care market. The market may be underestimating the long-term growth potential of Hinge Health as it continues to innovate and expand its product offerings.
Hinge Health's client base and distribution scale are described as "difficult-to-replicate," with nearly 3,000 clients, 60+ health plans, PBMs, and TPAs. This extensive distribution network provides the company with a significant competitive advantage and a strong foundation for future growth. The company's ability to leverage this distribution network to drive adoption of new products, such as the migraine care program, suggests that it is well-positioned to capitalize on future growth opportunities.

Hinge Health's Q1 FY26 results demonstrated strong momentum, with revenue growing 47% year-over-year to $182 million, surpassing guidance. This growth was driven by the strength of their platform, which automates care delivery, improves member outcomes, and lowers costs. The company's calculated billings for the last twelve months reached $770 million, reflecting a 52% growth from the previous year. This performance indicates a robust demand for their services and a scalable business model that is efficiently leveraging AI and automation to drive growth. The company's ability to consistently outperform expectations suggests that the market may be underestimating the long-term growth prospects of Hinge Health, particularly as they expand into new areas such as migraine care.
The launch of the migraine care program represents a significant growth catalyst for Hinge Health. The program has already been adopted by over 125 clients, representing more than 2 million eligible lives, within weeks of its launch. This rapid adoption underscores the strong demand for the company's innovative solutions and the potential for significant revenue growth in the future. The migraine care program leverages the company's existing platform capabilities, including the Enso neuromodulation device, which has received FDA 510(k) clearance for migraine care. This expansion into adjacent conditions demonstrates the company's ability to leverage its proprietary data and distribution network to drive future growth. The market may be underestimating the revenue impact of this program, which is expected to be meaningful beginning in 2027.
Hinge Health's financial performance continues to demonstrate the scalability and durability of its business model. The company achieved a gross margin of 85% and an operating margin of 25% in Q1 FY26, reflecting continued care team and hardware efficiency as the platform scales. Free cash flow was $42 million, a tenfold increase year-over-year, resulting in a 23% margin. These strong financial metrics indicate that the company is generating significant cash flows, which can be reinvested in innovation and growth or returned to shareholders. The company's ability to scale efficiently while maintaining strong profitability suggests that it is well-positioned to capitalize on future growth opportunities.
The company's strategic investments in AI and operational efficiencies have enabled it to improve gross and operating margins while scaling member engagement. This has supported a meaningful ramp in both free cash flow and share repurchases. The company's ability to leverage AI to drive operational efficiencies and improve member engagement suggests that it is well-positioned to maintain its competitive advantage in the digital musculoskeletal (MSK) care market. The market may be underestimating the long-term growth potential of Hinge Health as it continues to innovate and expand its product offerings.
Hinge Health's client base and distribution scale are described as "difficult-to-replicate," with nearly 3,000 clients, 60+ health plans, PBMs, and TPAs. This extensive distribution network provides the company with a significant competitive advantage and a strong foundation for future growth. The company's ability to leverage this distribution network to drive adoption of new products, such as the migraine care program, suggests that it is well-positioned to capitalize on future growth opportunities.

▼ Bear case

During the Q&A session, management's evasive response to the CMS ACCESS program raises concerns about potential regulatory risks. The company's decision not to participate in the program, citing concerns about clinical oversight and triple aim alignment, suggests that there may be underlying regulatory challenges that could impact the company's growth prospects. The market may be ignoring the potential for regulatory headwinds that could limit the company's ability to expand its services and drive revenue growth.
The company's yield (percentage of engaged eligible lives) is currently trending "slightly north of 4%," with a long-term target of 9% to 15%. While this indicates progress, the market may be ignoring the challenges associated with achieving this target. The company's ability to engage members and drive adoption of its platform will be critical to achieving this goal, and any setbacks in this area could impact the company's revenue and profitability.
The company's reliance on AI and automation to drive operational efficiencies and improve member engagement may be a double-edged sword. While these technologies have enabled the company to scale efficiently, they also introduce risks related to data security, privacy, and the potential for technical failures. The market may be ignoring the potential for these risks to impact the company's operations and reputation.
The company's expansion into the migraine care program, while promising, also introduces new risks and challenges. The market may be ignoring the potential for setbacks in the development and commercialization of this new program, which could impact the company's revenue and profitability. Additionally, the company's ability to successfully integrate this new program into its existing platform will be critical to its long-term success.
The company's decision not to participate in the CMS ACCESS program may limit its ability to access a significant portion of the healthcare market. The market may be ignoring the potential for this decision to impact the company's growth prospects, particularly as the healthcare landscape continues to evolve.

During the Q&A session, management's evasive response to the CMS ACCESS program raises concerns about potential regulatory risks. The company's decision not to participate in the program, citing concerns about clinical oversight and triple aim alignment, suggests that there may be underlying regulatory challenges that could impact the company's growth prospects. The market may be ignoring the potential for regulatory headwinds that could limit the company's ability to expand its services and drive revenue growth.
The company's yield (percentage of engaged eligible lives) is currently trending "slightly north of 4%," with a long-term target of 9% to 15%. While this indicates progress, the market may be ignoring the challenges associated with achieving this target. The company's ability to engage members and drive adoption of its platform will be critical to achieving this goal, and any setbacks in this area could impact the company's revenue and profitability.
The company's reliance on AI and automation to drive operational efficiencies and improve member engagement may be a double-edged sword. While these technologies have enabled the company to scale efficiently, they also introduce risks related to data security, privacy, and the potential for technical failures. The market may be ignoring the potential for these risks to impact the company's operations and reputation.
The company's expansion into the migraine care program, while promising, also introduces new risks and challenges. The market may be ignoring the potential for setbacks in the development and commercialization of this new program, which could impact the company's revenue and profitability. Additionally, the company's ability to successfully integrate this new program into its existing platform will be critical to its long-term success.
The company's decision not to participate in the CMS ACCESS program may limit its ability to access a significant portion of the healthcare market. The market may be ignoring the potential for this decision to impact the company's growth prospects, particularly as the healthcare landscape continues to evolve.

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password